GlassScriptPhysician profile
Loreen Ruiz
NPI 1376919621
$7,626.25
in general payments reported to CMS, 2019-2025
54 companies · $944 in 2025
The $944 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,481 · 2022: $1,679 · 2023: $1,862 · 2024: $661 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $777.25 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.46 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $606.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $584.04 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $572.65 | 2021-2025 | Freestyle Libre 3 |
| Mallinckrodt Hospital Products INC. | $524.48 | 2021-2024 | Acthar |
| Abbvie INC. | $475.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.35 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $321.13 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $261.06 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $220.92 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.48 | 2021-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $137.09 | 2021-2025 | Zoryve, Seglentis, Livalo |
| Exact Sciences Corporation | $132.96 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $122.09 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loreen Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.